Graybug Vision (GRAY) Stock Price, News & Analysis

Company Overview

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for retinal diseases. The company’s proprietary Depot Technology Platform is designed to deliver sustained-release formulations of biologically active agents directly to the back of the eye, with the goal of reducing treatment burden and improving patient outcomes. Graybug’s lead product candidate, GB-102, is a long-acting formulation of sunitinib malate being investigated for the treatment of wet age-related macular degeneration (wet AMD). The company is also advancing GB-401, a sustained-release formulation of travoprost for the management of open-angle glaucoma.

Graybug Vision’s clinical development program for GB-102 has included Phase I/II studies in patients with wet AMD, demonstrating a favorable safety profile and potential for extended dosing intervals compared to existing standards of care. The company has expanded its clinical footprint into multiple centers across the United States and has established collaborations with ophthalmology specialists to support ongoing and future trials. In parallel, preclinical and early clinical work on GB-401 aims to address unmet needs in glaucoma management by offering sustained intraocular pressure control without the need for daily eye drops.

Founded with the mission of transforming ophthalmology through sustained-delivery technologies, Graybug Vision is headquartered in New York City. The company is led by President and Chief Executive Officer David R. Guyer, M.D., who brings over two decades of experience in ophthalmic drug development. Under his leadership, Graybug has assembled a team with deep expertise in pharmacology, formulation science, and clinical trial execution, positioning the company to advance its pipeline and explore additional indications for its Depot Technology Platform.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.58 to $1.06
• 52-Week Range: N/A
• Volume: 2.99 million shs
• Average Volume: 2,165 shs
• Market Capitalization: $1.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/11/2021
• Today: 7/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:GRAY
• CIK: 1534133
• Web: www.graybug.com
• Phone: N/A
• Fax: N/A
• Employees: 27
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): ($24.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.60 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -77.61%
• Return on Assets: -71.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.73
• Quick Ratio: 10.72

Sales & Book Value

• Annual Sales: $426.96 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.67 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,571,000
• Free Float: 20,250,000
• Market Cap: $1.67 million
• Optionable: Not Optionable
• Beta: 1.20